Expect closer supervision of US biologics settlements in wake of Humira ‘reverse payment’ concerns
Two US senators have called on the Federal Trade Commission (FTC) to examine patent settlements involving biologic and biosimilar producers, echoing calls from patient advocacy groups. Raising particular concerns about AbbVie’s recent high-profile…
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10